"Angst about the pending high-risk AML readout may be detracting from the valuation of the clinical-stage remainder of the [Cyclacel] pipeline. In our view, the positive risk/reward has less to do with the odds of success (which have not changed) and more to do with the depressed valuation ahead of the readout."
Andrew Fein, H.C. Wainwright analyst, on Cyclacel Pharmaceuticals Inc.'s soon-to-report, phase III SEAMLESS trial in acute myeloid leukemia

"We have a pretty fat portfolio of anti-CD47 antibodies, and we wanted to put together a syndicate and a financing amount that would allow us to do the right scope of work, test these things in the clinic and determine if, how and to what extent CD47 inhibition benefits patients suffering from cancer."
John Donovan, president and CEO, Tioma Therapeutics Inc., on its $86 million series A round to support development of a pipeline of anti-CD47 antibodies to treat solid and hematologic cancers

"The goal of Exac over the past three years was to create a database of normal variation at a massive scale."
Daniel MacArthur, of the Broad Institute of MIT and Harvard and lead author in a paper in Nature analyzing genetic variation in the protein-coding exomes of 60,706 healthy volunteers. The researchers behind the Exome Aggregation Consortium (Exac) said the data provide unprecedented resolution into low frequency protein-coding variants and will make it easier to identify clinically relevant genetic variation in human disease